Migraine Prophylaxis: Beta-Blockers, Topiramate, CGRP Monoclonals, Gepants, and Botox for Chronic Migraine
Evidence-based preventive therapy framework spanning indications, oral first-line agents, CGRP-targeted monoclonal antibodies, oral gepants, onabotulinumtoxinA for chronic migraine, and lifestyle modification – with practical titration schedules, comorbidity-driven selection, and treatment-failure escalation pathways.
Executive Summary
Migraine affects approximately 14% of adults globally, yet only 12-13% of eligible patients with episodic migraine and 26-45% with chronic migraine receive preventive therapy despite clear indications. Initiate prophylaxis when monthly migraine days reach 4 or more, when MIDAS disability is moderate-to-severe regardless of frequency, when acute medication overuse is occurring, or for high-risk migraine subtypes (hemiplegic, brainstem aura, status migrainosus). First-line oral preventives are selected by comorbidity profile: propranolol 80-240 mg/day or metoprolol for hypertension, topiramate 50-100 mg/day for obesity, amitriptyline 25-100 mg QHS for insomnia and tension overlap, and valproate 500-1500 mg/day for comorbid epilepsy (avoid in pregnancy-capable patients). CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) deliver superior tolerability and 30-50% responder rates after oral failure – and are increasingly used first-line. Oral CGRP gepants (atogepant, rimegepant) offer prevention without injection. OnabotulinumtoxinA 155 units q12 weeks across 31 PREEMPT sites is reserved for chronic migraine (15+ headache days/month). Trial each oral agent for 8-12 weeks at target dose, CGRP mAbs for 3 months, and Botox for 2 cycles before declaring failure. Combine pharmacotherapy with the SEEDS lifestyle framework (Sleep, Exercise, Eat, Diary, Stress) for maximal benefit.
1. Pathophysiology and Indications for Prophylaxis
Trigeminovascular Activation and the CGRP Cascade
Migraine is now understood as a primary brain disorder rather than a vascular phenomenon. Cortical spreading depression (CSD), a slowly propagating wave of neuronal and glial depolarization, underlies the visual and sensory aura phase. CSD activates trigeminal afferents in the meninges, releasing vasoactive neuropeptides – principally calcitonin gene-related peptide (CGRP), substance P, and pituitary adenylate cyclase-activating polypeptide (PACAP) – producing neurogenic inflammation, dural vasodilation, and central sensitization at the trigeminal nucleus caudalis and thalamus.
CGRP is the dominant neuropeptide driver: jugular venous CGRP rises during attacks, IV CGRP reproducibly triggers migraine in susceptible individuals, and blocking CGRP signaling (via monoclonal antibodies against the ligand or receptor, or via small-molecule receptor antagonists called gepants) prevents attacks. This biology has revolutionized prophylaxis since 2018, providing the first migraine-specific preventive class. Hypothalamic involvement explains premonitory symptoms (yawning, food cravings, mood changes) and the predictable response to circadian and sleep disruption.
Chronic migraine (15+ headache days/month with 8+ migraine days for ≥3 months) reflects progressive central sensitization, with cortical thickening, reduced periaqueductal gray volume, and impaired diffuse noxious inhibitory control. Risk factors for chronification include high baseline attack frequency, acute medication overuse, obesity, sleep disorders, depression, and untreated comorbidities. Effective prophylaxis can reverse chronification – making early preventive therapy a disease-modifying intervention, not just symptom control.
When to Initiate Preventive Therapy
The American Headache Society 2024 consensus statement and AAN/AHS guidelines recommend prophylaxis when any of the following apply:
- Frequency: 4 or more migraine days per month, OR 6 or more headache days per month with some impairment, OR 3 or more days with severe impairment.
- Disability: MIDAS Grade III (11-20 days lost) or Grade IV (21+ days lost) regardless of attack frequency.
- Acute treatment failure or contraindication: ineffective or poorly tolerated triptans/NSAIDs, or vascular contraindications precluding triptan use.
- Medication overuse risk: triptan or opioid use 10+ days/month, ergot use 10+ days/month, or simple analgesic use 15+ days/month.
- Special migraine subtypes: hemiplegic migraine, migraine with brainstem aura, persistent aura without infarction, or migrainous infarction history (because acute triptans are contraindicated).
- Patient preference: when attacks meaningfully disrupt life despite lower frequency.
⚠️ Counsel patients on realistic expectations
Successful prophylaxis is defined as 50% reduction in monthly migraine days, not elimination. Onset of benefit is gradual: 4-8 weeks for oral agents, 4-12 weeks for CGRP mAbs, and 6 months (2 cycles) for Botox. Patients abandoning therapy at week 2-3 because “it didn’t work” represents the most common reason for prophylaxis failure.
2. Diagnostic Framework and Severity Stratification
ICHD-3 Migraine Classification
The International Classification of Headache Disorders, 3rd edition (ICHD-3) defines migraine subtypes used for prophylaxis decisions:
| Subtype | ICHD-3 Criteria (Summary) | Prophylaxis Implication |
|---|---|---|
| Migraine without aura | ≥5 attacks lasting 4-72 h, with ≥2 of (unilateral, pulsating, moderate-severe, aggravated by activity) PLUS ≥1 of (nausea/vomiting, photophobia+phonophobia) | Standard prophylaxis criteria apply |
| Migraine with aura | ≥2 attacks with ≥1 reversible aura (visual, sensory, speech, motor, brainstem, retinal) lasting 5-60 min | Avoid combined oral contraceptives – increased stroke risk; preventives strongly indicated |
| Episodic migraine | <15 headache days/month | Oral preventives or CGRP mAb/gepant |
| Chronic migraine | ≥15 headache days/month for ≥3 months, with ≥8 days fulfilling migraine criteria | Botox 155 U eligible; CGRP mAbs preferred; reverse medication overuse |
| Status migrainosus | Debilitating attack lasting >72 h despite treatment | Hospital admission, IV bridge therapy, urgent prophylaxis initiation |
| Hemiplegic migraine | Aura with motor weakness; familial (CACNA1A, ATP1A2, SCN1A) or sporadic | Triptans contraindicated; verapamil, lamotrigine, or CGRP mAb preferred |
| Vestibular migraine | Recurrent vertigo with migraine features (current/historical) | Standard prophylaxis (topiramate, propranolol, amitriptyline, venlafaxine) |
| Medication overuse headache | Headache ≥15 days/month + regular overuse for ≥3 months (triptan/opioid/ergot ≥10 d/mo, analgesic ≥15 d/mo) | Withdraw offending agent + start prophylaxis simultaneously |
Disability Scoring: MIDAS and HIT-6
MIDAS (Migraine Disability Assessment): Patient reports days lost (work, household, social) over preceding 3 months. Total score categorizes disability:
- Grade I (0-5): Little or no disability – prophylaxis optional
- Grade II (6-10): Mild disability – consider prophylaxis
- Grade III (11-20): Moderate disability – prophylaxis recommended
- Grade IV (21+): Severe disability – prophylaxis strongly recommended, consider CGRP mAb first-line
HIT-6 (Headache Impact Test): 6-question instrument scored 36-78. HIT-6 ≥60 indicates severe impact. Both MIDAS and HIT-6 should be repeated every 3 months to track treatment response objectively.
3. Oral First-Line Preventives by Comorbidity
Selection Strategy: Match Drug to Comorbidity
The single most useful clinical heuristic is comorbidity-driven selection. The right preventive treats two problems with one drug, improving adherence and outcomes:
| Comorbidity / Patient Profile | Preferred Preventive | Rationale |
|---|---|---|
| Hypertension, anxiety, performance-induced tachycardia | Propranolol 80-240 mg/day or metoprolol 100-200 mg/day | Beta-blockade treats both BP and migraine |
| Obesity, idiopathic intracranial hypertension | Topiramate 50-100 mg/day | Weight loss benefit, also lowers ICP |
| Insomnia, depression, tension headache overlap | Amitriptyline 25-100 mg QHS or nortriptyline 25-75 mg QHS | TCA addresses sleep, mood, and pain modulation |
| Comorbid epilepsy (not pregnancy-capable) | Valproate 500-1500 mg/day | Antiseizure + migraine prevention |
| Comorbid generalized anxiety, fibromyalgia | Venlafaxine ER 75-150 mg/day or duloxetine 60 mg/day | SNRI dual benefit |
| Vestibular migraine | Topiramate, propranolol, or venlafaxine first-line | All have supportive vestibular migraine evidence |
| Hemiplegic migraine | Verapamil 240-480 mg/day or lamotrigine 100-200 mg/day | Avoid triptans/topiramate; verapamil for prevention |
| Hypertension with avoiding beta-blocker | Candesartan 16 mg/day or lisinopril 20 mg/day | ARB/ACEi efficacy proven for migraine prevention |
| Pregnancy or planning pregnancy | Magnesium oxide 400-600 mg/day, riboflavin 400 mg/day, propranolol (lowest effective dose) | Avoid topiramate (cleft palate), valproate (NTD), TCAs (third trimester) |
Titration Schedules and Target Doses
Propranolol
Start propranolol 20-40 mg PO BID (or extended-release 60-80 mg daily). Increase by 20-40 mg/day every 1-2 weeks to target 80-240 mg/day divided BID-TID (or once-daily ER). Maximum dose 320 mg/day. Monitor heart rate (target HR 55-65 bpm at rest), blood pressure, and tolerance of fatigue/cold extremities. Avoid in asthma, severe COPD, second/third-degree AV block, decompensated heart failure, and Raynaud disease. Trial 8-12 weeks at target dose before declaring failure.
Topiramate
Start topiramate 25 mg PO QHS. Increase by 25 mg/week to target 50-100 mg/day divided BID. Maximum 200 mg/day. Common adverse effects: paresthesias (50%, mitigated by increased fluid intake), cognitive slowing (“dopamax” effect, 20-30%), weight loss (5-10%, often desired), and rare but serious risks – acute angle-closure glaucoma (warn patient about acute eye pain/vision loss in first weeks), kidney stones (5%, encourage hydration and avoid carbonic anhydrase combo), oligohidrosis with hyperthermia (especially pediatric), and metabolic acidosis. Pregnancy category D – cleft lip/palate risk. Counsel on contraception. Trial 8-12 weeks at target dose.
Amitriptyline
Start amitriptyline 10-25 mg PO QHS, taken 2-3 hours before bedtime to mitigate morning grogginess. Increase by 10-25 mg every 1-2 weeks to target 25-100 mg QHS. Maximum 150 mg/day for migraine. Anticholinergic adverse effects (dry mouth, constipation, urinary retention, blurred vision) and weight gain are common. Cardiac effects: prolonged QT interval – obtain baseline ECG if dose >75 mg/day or with cardiac risk factors. Avoid concurrent MAOIs, tramadol, linezolid (serotonin syndrome). Nortriptyline 25-75 mg QHS is a less anticholinergic alternative for elderly patients.
Valproate (Divalproex)
Start divalproex 250 mg PO BID. Increase to target 500-1500 mg/day divided BID-TID. Pregnancy category X for migraine – absolute contraindication in pregnancy-capable patients (neural tube defects, neurodevelopmental impairment). Monitor LFTs, CBC, ammonia, and trough valproate level (target 50-100 mcg/mL for migraine). Adverse effects: hepatotoxicity (rare but fatal in young children and patients with mitochondrial disease), pancreatitis, hyperammonemic encephalopathy, weight gain, hair loss, tremor, thrombocytopenia.
CGRP-Adjacent Oral Options
Beyond traditional preventives, several agents deserve consideration:
- Candesartan 16 mg PO daily – randomized trial evidence comparable to propranolol; useful when BP also needs control or beta-blocker contraindicated.
- Memantine 5-20 mg PO daily – small studies show benefit for refractory migraine via NMDA antagonism.
- Magnesium oxide 400-600 mg PO daily – mild benefit; loose stools dose-limiting; especially useful in menstrual migraine and pregnancy.
- Riboflavin (vitamin B2) 400 mg PO daily – requires 3 months for effect; benign side effect profile.
- Coenzyme Q10 100 mg PO TID – mitochondrial mechanism; modest evidence.
- Feverfew 50-100 mg PO daily – herbal; modest evidence and variable potency.
💎 Pearl: Start low, titrate slowly, document response objectively
The most common reason patients label preventives as “ineffective” is dose-limiting side effects encountered during fast titration. Topiramate at 50 mg/day reached over 8 weeks is dramatically better tolerated than 50 mg achieved in 2 weeks. Use a structured headache diary or app (Migraine Buddy, N1-Headache) and review at 4 weeks (tolerance), 8 weeks (early response), and 12 weeks (final assessment). Document baseline MMD – many patients underestimate frequency and discount real improvement.
⚠️ Pitfall: Polypharmacy without clear sequencing
Adding a second oral preventive while still titrating the first – or stacking three classes simultaneously – obscures attribution and accumulates side effects. Optimize one agent at target dose for 8-12 weeks before sequential rotation or combination. Document failure (drug, max tolerated dose, duration, reason for stopping) – this record supports CGRP mAb prior authorization, which usually requires 2 documented oral failures.
4. CGRP Monoclonal Antibodies and Oral Gepants
Mechanism: Blocking the CGRP Pathway
CGRP-targeted therapies represent the first migraine-specific preventive class. Two strategies exist: (1) monoclonal antibodies binding CGRP ligand (fremanezumab, galcanezumab, eptinezumab) or its receptor (erenumab), and (2) small-molecule oral receptor antagonists called gepants (atogepant, rimegepant, ubrogepant). Both interrupt trigeminal neurogenic inflammation and central sensitization.
Monoclonal Antibodies for Episodic and Chronic Migraine Prevention
| Drug | Target | Dose / Route | Onset | Key Notes |
|---|---|---|---|---|
| Erenumab (Aimovig) | CGRP receptor | 70 mg or 140 mg SC monthly | Within 1 week (some by month 3) | Constipation (most common), hypertension worsening (FDA warning), injection site reactions |
| Fremanezumab (Ajovy) | CGRP ligand | 225 mg SC monthly OR 675 mg SC quarterly | Within 4-12 weeks | Quarterly dosing improves adherence; injection site reactions |
| Galcanezumab (Emgality) | CGRP ligand | 240 mg SC loading → 120 mg SC monthly | Within 1-2 months | Also approved for episodic cluster headache; injection site reactions |
| Eptinezumab (Vyepti) | CGRP ligand | 100 mg or 300 mg IV q3 months | Day 1 (RELIEF trial) | Fastest onset; useful for status migrainosus or rapid response need; infusion required |
Pivotal Trial Data Summary
Across STRIVE (erenumab episodic), HALO-EM/HALO-CM (fremanezumab), EVOLVE-1/2 (galcanezumab episodic), REGAIN (galcanezumab chronic), PROMISE-1/2 (eptinezumab), and DELIVER (erenumab in 2-4 prior failures), CGRP mAbs consistently demonstrate:
- 50% responder rate of 40-60% for episodic migraine and 25-40% for chronic migraine.
- MMD reduction of 3-4 days from baseline of 8-12 days/month.
- Discontinuation rates due to adverse events under 5% across all agents – dramatically better tolerated than oral preventives.
- Efficacy maintained across patients with multiple prior preventive failures.
Practical Use, Insurance, and Switching
Most US/EU payers require documented failure/intolerance of 2 oral preventives from different classes before approving a mAb. Many specialty pharmacies and patient assistance programs cover copays. Assess response at 3 months: continue if 50% or greater MMD reduction or meaningful disability improvement; switch within class if non-responder (some patients respond to receptor blockade after ligand failure or vice versa). After 12 months of sustained benefit, consider treatment holiday in carefully selected patients – expect 30-40% to retain remission for 3+ months off therapy.
🚨 Erenumab and Cardiovascular Safety
Post-marketing reports of new-onset or worsened hypertension led to a 2020 FDA label update. Check baseline BP, monitor at month 1 and quarterly thereafter, and consider non-receptor mAb (fremanezumab, galcanezumab, eptinezumab) for patients with uncontrolled hypertension, severe Raynaud phenomenon, or significant constipation. CGRP mAbs are not recommended in patients with active cardiovascular disease (MI, stroke, severe CAD) due to limited safety data.
Oral CGRP Gepants for Prevention
| Drug | Indication | Dose | Trial Evidence | Notes |
|---|---|---|---|---|
| Atogepant (Qulipta) | Episodic and chronic migraine prevention | 10, 30, or 60 mg PO daily | ADVANCE (episodic), PROGRESS (chronic) – significant MMD reduction at 12 weeks | First fully oral CGRP-targeted preventive; well tolerated; dose adjust for severe renal/hepatic impairment |
| Rimegepant (Nurtec ODT) | Episodic migraine prevention AND acute treatment (dual-use) | 75 mg PO every other day for prevention | Phase 2/3 prevention trials; meaningful MMD reduction | Only drug with both acute and preventive labels; useful for menstrual migraine and patients preferring single-drug regimen |
| Ubrogepant (Ubrelvy) | Acute treatment only (not approved for prevention as of 2026) | 50 or 100 mg PO PRN per attack | ACHIEVE-I/II for acute | Useful as acute rescue when triptans contraindicated; avoid strong CYP3A4 inhibitors |
When to choose a gepant over a mAb: patient prefers oral therapy, needle phobia, intermittent prevention need (perimenstrual or seasonal), insurance barriers to mAb approval, or as bridge therapy while awaiting mAb authorization. Avoid gepants with strong CYP3A4 inhibitors (clarithromycin, itraconazole, ketoconazole, ritonavir) which substantially raise gepant exposure.
💎 Pearl: Rimegepant for menstrual migraine and dual-purpose therapy
Rimegepant 75 mg every other day for prevention plus 75 mg PRN for breakthrough attacks (max 1 dose/day) is uniquely useful for women with menstrual migraine – they can preventively dose during the perimenstrual window and use the same drug acutely. This dual-use property eliminates the medication overuse headache concern that complicates triptan-based regimens, since gepants do not appear to cause MOH.
⚠️ Pitfall: Switching mAbs without documenting non-response
Insurance step-therapy and step-edits often deny a second CGRP mAb without documented 3-month trial of the first. Always record baseline MMD, MIDAS, HIT-6 before starting; reassess at 3 months; and document the specific reason for switch (insufficient efficacy by quantitative metrics, intolerable adverse effect, patient preference). Switching from a receptor antagonist (erenumab) to a ligand antibody (fremanezumab/galcanezumab/eptinezumab) – or vice versa – rescues response in 30-40% of initial non-responders.
5. OnabotulinumtoxinA, Combination Therapy, and Refractory Migraine
OnabotulinumtoxinA (Botox) – PREEMPT Protocol
Botox is FDA-approved for chronic migraine (15+ headache days/month for 3+ months with at least 8 migraine days/month). It is NOT effective and not indicated for episodic migraine (less than 15 days/month). The standard PREEMPT protocol delivers 155 units total across 31 fixed injection sites every 12 weeks: 5 units per site at corrugator (×2), procerus (×1), frontalis (×4), temporalis (×8), occipitalis (×6), cervical paraspinal (×4), and trapezius (×6). An additional 40 units may be added at “follow-the-pain” sites for a maximum 195 units per cycle.
Mechanism: Botox blocks acetylcholine release at peripheral nerve terminals AND inhibits release of neuropeptides (CGRP, substance P, glutamate) and TRPV1/TRPA1 channel insertion at peripheral trigeminal nociceptors. Onset is gradual, typically requiring 2 cycles (6 months) to assess response. PREEMPT trials demonstrated reduction of approximately 8 headache days per month from baseline of 19-20 days. Adverse effects: neck pain (most common, 9%), eyelid ptosis (3%), brow ptosis, muscle weakness, injection site discomfort.
Combination Therapy
Most chronic migraine patients require multimodal therapy. Reasonable combinations include:
- Oral preventive + CGRP mAb: Continue topiramate or amitriptyline while adding mAb; reassess oral need at 6 months – many can taper.
- Botox + CGRP mAb: Increasingly common for refractory chronic migraine. Evidence from FORWARD and observational studies suggests additive benefit.
- Botox + oral preventive: Standard for chronic migraine when Botox alone insufficient.
- Avoid combining triptans with high-dose ergots or with MAOIs – serotonin syndrome risk.
Bridge Therapy for Status Migrainosus
For severe refractory attacks lasting more than 72 hours despite oral therapy, consider:
- IV/IM antiemetics: metoclopramide 10 mg IV, prochlorperazine 10 mg IV (give diphenhydramine 25 mg to prevent akathisia)
- IV ketorolac: 30 mg IV (15 mg if elderly or renal impairment)
- IV magnesium sulfate: 1-2 g IV over 15 minutes (especially for migraine with aura)
- IV valproate: 500-1000 mg over 15-30 minutes
- IV dihydroergotamine (DHE) protocol: 0.5-1 mg IV q8h with antiemetic premed for 3-5 days (Raskin protocol); contraindicated with vascular disease, sepsis, or recent triptan use (24-hour washout)
- Greater occipital nerve block: 5 mL of 1-2% lidocaine ± 4 mg dexamethasone bilateral GON injection – rapid relief in 50-70%
- Short course oral steroid: dexamethasone 4 mg PO daily × 4 days OR methylprednisolone dose pack to break the cycle
- Eptinezumab 300 mg IV: Onset within 24 hours per RELIEF subgroup analysis
When to Refer to a Headache Specialist
📋 Refer to headache neurology when:
Refractory disease: failure of 3+ preventives across 2+ classes including a CGRP-targeted agent. Diagnostic uncertainty: features atypical for migraine, new headache after age 50, thunderclap headache, or progressive headache. Special subtypes: hemiplegic migraine, migraine with brainstem aura, status migrainosus requiring repeated ED visits, persistent aura without infarction, migrainous infarction. Procedural needs: Botox initiation, sphenopalatine ganglion block, occipital nerve stimulation, or neuromodulation device evaluation. Pregnancy planning: woman with chronic migraine planning conception. Medication overuse headache requiring inpatient withdrawal protocol.
Neuromodulation Devices (Non-Pharmacologic)
FDA-cleared devices provide drug-free options for patients who prefer non-pharmacologic therapy, are pregnant, or are refractory to medications:
- Cefaly (e-TNS): external trigeminal nerve stimulator worn on forehead 20 minutes daily for prevention; evidence from PREMICE trial.
- gammaCore (nVNS): non-invasive vagus nerve stimulator; FDA approved for acute and preventive treatment of episodic migraine and cluster headache.
- Nerivio: remote electrical neuromodulation arm-band for acute treatment.
- sTMS (single-pulse transcranial magnetic stimulation): handheld device for acute migraine with aura.
- Relivion: combined occipital + trigeminal nerve stimulator for acute treatment.
Practice Insights: What Tends to Drive Migraine Prophylaxis Decisions
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Two months is the shortest honest trial of a migraine preventive and the longest most patients give one, which is why patients typically arrive on a single oral preventive that was either underdosed, mismatched to their comorbidity profile, or stopped at 4 weeks because the patient assumed it “didn’t work.” Two changes move chronic migraine outcomes most: matching the first-line preventive to comorbidity rather than tradition, and offering CGRP monoclonals as first-line rather than “after 3 oral failures” once the patient meets episodic/chronic thresholds.
Match the Preventive to the Comorbidity, Not the Habit
The biggest avoidable harm is starting amitriptyline reflexively in every patient — including overweight or obese patients who then gain 8–15 kg over the year on the drug, or starting topiramate in a patient with kidney stones (topiramate increases stone risk). In routine practice the first-line preventive should be chosen by comorbidity: HTN → propranolol 80–240 mg/day or metoprolol; depression → venlafaxine or amitriptyline; epilepsy → topiramate 100 mg/day or valproate; obesity → topiramate (modest weight loss); pregnancy or childbearing potential → propranolol first, AVOID topiramate and valproate. The “one-drug-for-all” approach is how migraine prophylaxis got its reputation for being ineffective when really the drug was wrong.
CGRP Monoclonals at the First Visit, Not After 3 Oral Failures
The AAN 2021 update positioned CGRP monoclonals as appropriate first-line for patients meeting prophylaxis criteria — they do not require failure of 2–3 oral preventives first. In routine practice erenumab 70–140 mg SC monthly, galcanezumab 240 mg load then 120 mg monthly, fremanezumab 225 mg monthly or 675 mg quarterly, or eptinezumab 100–300 mg IV every 3 months are offered at the diagnostic visit when patients have ≥4 migraine days per month with significant disability. The 3-month effect window is well-defined, so patients should be counseled to judge response at week 12, not week 4. Insurance authorization remains the practical bottleneck, but most plans now cover the class.
Atogepant and Rimegepant for Oral CGRP Convenience
For patients who reject injections, atogepant 60 mg daily (Qulipta, FDA approved for both episodic and chronic migraine as of 2023) is the preferred oral CGRP option. Rimegepant 75 mg every other day is a dual acute-plus-prevention agent with the unique property of treating an attack on dosing days. The oral gepants do not require titration, have no boxed warnings, and have minimal drug interactions — they fit patients who have failed or refused the injectables. Ubrogepant has no role in prevention; that one is acute-only.
Combination Therapy Beats Monotherapy in Chronic Migraine
The HOPE trial and accumulating real-world data show CGRP monoclonal plus oral preventive (typically topiramate or beta-blocker) gives better headache-day reduction than either alone in chronic migraine. The practical approach is to add the CGRP mAb on top of an existing well-tolerated oral preventive rather than replacing it, unless the oral agent is causing intolerable side effects. For severely refractory chronic migraine — ≥15 headache days/month despite optimized oral and CGRP therapy — add OnabotulinumtoxinA per PREEMPT protocol (155 units across 31 sites every 12 weeks). Triple therapy (oral + CGRP + Botox) is appropriate for the most refractory subset, with reassessment at 6 months.
Illustrative Scenario: Twelve Migraine Days to Five With Comorbidity-Matched Switch + CGRP
A woman in her early 40s presented with 12 migraine days per month and 8 disabled days per month — meeting chronic migraine criteria. She had been on amitriptyline 50 mg at bedtime for 18 months with partial response but had gained 12 kg over that time. Acute therapy was sumatriptan 100 mg PO with moderate response. BMI was now 31. Examination and MRI brain were unremarkable; medication overuse history showed sumatriptan use 8 days per month (below the 10-day threshold). Consider the comorbidity-matched course: switch from amitriptyline (weight gain in obesity) to topiramate, titrated 25 mg weekly to 100 mg daily, with erenumab 70 mg SC monthly started at the same visit. By month 3 migraine days had dropped to 5 per month and disabled days to 2 per month. She lost 4 kg on topiramate over the same period. Acute sumatriptan use dropped to 3 days per month. Stability at 12-month follow-up would then open the discussion of an eventual topiramate taper at the 18-month mark.
Takeaway: comorbidity-matched preventive switching plus CGRP mAb at the visit moves chronic migraine to controlled episodic migraine in months, not years. Waiting for 2–3 oral preventives to fail before considering CGRP is outdated thinking.
Protocol Adjustments Beyond the Standard Guideline
- First-line preventive matched to comorbidity, not habit — HTN propranolol, depression venlafaxine/amitriptyline, epilepsy topiramate/valproate, obesity topiramate, pregnancy propranolol. Avoid amitriptyline and valproate in obesity; avoid topiramate and valproate in childbearing potential.
- CGRP monoclonals at diagnostic visit for ≥4 migraine days/month with disability — not after 3 oral failures. Judge response at week 12, not week 4.
- Atogepant 60 mg daily for injection-averse patients — FDA approved for both episodic and chronic migraine. No titration, no boxed warnings, oral CGRP convenience. Rimegepant every other day for acute-plus-prevention dual use.
- Combination CGRP + oral preventive in chronic migraine — HOPE trial supports better headache-day reduction than monotherapy. Add Botox per PREEMPT protocol for ≥15 headache days/month refractory triple therapy.
6. Special Populations, Lifestyle, and FAQ
Pregnancy and Lactation
Migraine often improves in 60-70% of women during pregnancy (especially second/third trimester) due to estrogen stability. However, 8% experience worsening. Preferred preventives in pregnancy: magnesium oxide 400-600 mg/day, riboflavin 400 mg/day, propranolol (lowest effective dose, monitor fetal growth restriction), and amitriptyline (avoid third trimester due to neonatal withdrawal). Avoid: topiramate (cleft palate, low birth weight), valproate (neural tube defects, neurodevelopmental), CGRP mAbs (limited safety data, theoretical placental concerns), gepants (insufficient data), Botox (insufficient data). Acute treatment in pregnancy: acetaminophen, metoclopramide; triptans (sumatriptan most studied) in second/third trimester if benefit outweighs risk; avoid NSAIDs in third trimester. Lactation: most preventives compatible (propranolol, amitriptyline, magnesium); CGRP mAbs likely safe (large protein, minimal milk transfer) but limited data.
Menstrual Migraine
Pure menstrual migraine (occurring exclusively in the perimenstrual window, days -2 to +3) and menstrually-related migraine (additional non-menstrual attacks) affect up to 60% of female migraine sufferers. Specific approaches:
- Mini-prophylaxis: frovatriptan 2.5 mg BID × 6 days starting 2 days before expected menses, or naratriptan 1 mg BID × 5 days, or naproxen 550 mg BID × 7 days perimenstrually.
- Hormonal manipulation: continuous combined oral contraceptive (only if no aura – migraine with aura plus COC raises stroke risk significantly), or transdermal estradiol 100 mcg patch during pill-free week.
- Standard prophylaxis: daily oral preventives or CGRP mAb (especially fremanezumab quarterly dosing aligns well).
- Rimegepant 75 mg every other day with PRN dosing during attacks – particularly elegant solution.
Pediatric and Adolescent Migraine
Migraine affects 8-10% of children and 15-20% of adolescents. Initial approach prioritizes lifestyle and CBT. Pharmacologic preventives with pediatric evidence: topiramate (FDA-approved 12+ years, 50-100 mg/day), amitriptyline (off-label, 10-50 mg QHS), propranolol (off-label, 1-2 mg/kg/day). The CHAMP trial showed no superiority of amitriptyline or topiramate over placebo in pediatrics, raising the bar for non-pharmacologic approaches first. CGRP mAbs are not yet FDA-approved for under 18 (galcanezumab and erenumab approval expected based on ongoing trials). Botox is approved for chronic migraine in 18+ only.
Older Adults (Age 65+)
New-onset migraine after 50 mandates secondary headache workup (giant cell arteritis, intracranial mass, subdural hematoma, medication-induced). For established migraine:
- Lower starting doses; slower titration.
- Avoid TCAs at high dose (anticholinergic burden, falls, confusion); use nortriptyline preferentially.
- Caution with topiramate (cognitive effects, falls).
- Beta-blockers safe but watch for bradycardia, orthostasis, depression.
- CGRP mAbs preferred for tolerability profile, but caution with cardiovascular comorbidity.
- Avoid triptans with established CAD, CVD, peripheral vascular disease.
Lifestyle: The SEEDS Framework
The American Migraine Foundation SEEDS protocol summarizes high-yield non-pharmacologic interventions:
- S – Sleep: consistent bedtime/waketime within 1 hour daily; 7-9 hours; treat OSA if present.
- E – Exercise: 150 minutes/week moderate aerobic activity; modest evidence equivalent to topiramate (Varkey 2011).
- E – Eat: regular meals, avoid skipping; adequate hydration (2 L/day); cautious with alcohol (red wine especially).
- D – Diary: headache diary identifying triggers, patterns, response to treatment.
- S – Stress: CBT, biofeedback, mindfulness-based stress reduction – all with Class A evidence.
Acute Treatment Overview (Brief)
Although this article focuses on prevention, acute treatment selection influences prophylaxis decisions. Standard acute therapy:
- Mild-moderate: NSAIDs (ibuprofen 600-800 mg, naproxen 500-1000 mg, ketorolac 30 mg IM), acetaminophen 1000 mg, combination analgesics (acetaminophen-ASA-caffeine).
- Moderate-severe: triptans – sumatriptan 50-100 mg PO (or 6 mg SC for severe attacks), rizatriptan 10 mg ODT, eletriptan 40 mg, almotriptan, frovatriptan (longest half-life), naratriptan (slowest onset).
- Triptan-contraindicated (vascular disease): ditans (lasmiditan 100-200 mg PO – causes driving impairment ×8 hours), gepants (ubrogepant 50-100 mg, rimegepant 75 mg ODT).
- Adjuncts: antiemetics (metoclopramide 10 mg, prochlorperazine 10 mg), early treatment (within 30-60 min of pain onset improves response).
- Refractory ED: IV metoclopramide + diphenhydramine + ketorolac + IV fluids; IV magnesium for migraine with aura; greater occipital nerve block.
⚠️ Medication Overuse Headache – critical to identify and treat
Frequent acute medication use paradoxically transforms episodic to chronic migraine. Thresholds: triptans/opioids/ergots/combination analgesics ≥10 days/month, simple analgesics ≥15 days/month, all for ≥3 months. Treatment requires (1) withdrawal of overused agent (abrupt for triptans/NSAIDs/acetaminophen, gradual taper for opioids/butalbital), (2) bridge therapy (steroid taper, GON block, IV DHE), (3) simultaneous initiation of an effective preventive (CGRP mAb is ideal – does not exacerbate MOH and can be started during withdrawal). Patients often experience initial worsening for 2-4 weeks before improvement.
Frequently Asked Questions
- Unruptured Cerebral Aneurysm Screening: Who, When, and How
- Aneurysmal Subarachnoid Hemorrhage: Chronic & Long-Term Management
- Brain AVM: Spetzler-Martin Grading, Hemorrhage Risk, and Treatment Decision-Making
- Adult Spinal Cord Tumors: Classification, Imaging, and Surgical Management
- Intracerebral Hemorrhage: Acute Blood Pressure, Anticoagulation Reversal, and Surgical Indications
- Idiopathic Intracranial Hypertension: Diagnosis and Management